Molecular imaging (MI) originated from the need to better understand the fundamental molecular pathways inside organisms in a noninvasive manner. Over the past two decades, two factors have acted in concert to fuel the ascent of molecular imaging in both the laboratory and the clinic: First, an increased understanding of the molecular mechanisms of disease and second, the continued development of in vivo imaging technologies, ranging from improved detectors to novel labeling methodologies. The advent of molecular imaging has, in turn, prompted a paradigm shift in medical imaging as a whole, from its foundations in purely anatomical imaging towards techniques aimed at probing tissue phenotype and function. We have for many years exploited aberrant targets associated with cancer in order to better diagnose, stage, monitor and treat this disease.
The use of Positron Emission Tomography (PET) for cancer imaging is a well-established and widely used molecular imaging modality both in clinical and research settings. Over the last 30 years, our ability to non-invasively diagnose, localize, and treat many forms of cancer has advanced tremendously. Due to their exquisite selectivity and specificity for cancer biomarkers, radiolabeled antibodies have played an important and growing role in this trend. Within the last half-decade, antibodies have emerged as enticing tools for the PET imaging of cancer and endoradiotherapy and will be the focus of this presentation.
Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of prostate cancer. Gastrin-releasing peptide receptor (GRPR) -targeting radiopharmaceuticals are not as widely accepted as the prostate-specific membrane antigen (PSMA)-targeting ones. However, GRPR still are a valuable class of radiopharmaceuticals even when compared with PSMA in the evaluation of prostate cancer. The presentation will provide data to support this statement.
Dr. Iagaru is a Professor of Radiology - Nuclear Medicine and the Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University Medical Center. He completed medical school at Carol Davila University of Medicine, Bucharest, Romania, and an internship at Drexel University College of Medicine, Graduate Hospital, in the Department of Medicine in Philadelphia. He began his residency at the University of Southern California (USC) Keck School of Medicine, Los Angeles, in the Division of Nuclear Medicine, where he was the chief resident. Dr. Iagaru finished his residency and completed a PET/CT fellowship at Stanford University's School of Medicine in the Division of Nuclear Medicine. His research interests include PET/MRI and PET/CT for early cancer detection; clinical translation of novel PET radiopharmaceuticals; peptidebased diagnostic imaging and therapy; targeted radionuclide therapy.
Over the past 14 years since joining the faculty at Stanford, Dr. Iagaru has received several awards including the Society of Nuclear Medicine (SNM) 2009 Image of the Year Award; AuntMinnie 2016 Best Radiology Image, American College of Nuclear Medicine (ACNM) Mid-Winter Conference 2010 Best Essay Award; 2009, 2014 and 2015 Western Regional SNM Scientist Award; 2011 SNM Nuclear Oncology Council Young Investigator Award; and the 2020 Sanjiv Sam Gambhir Distinguished Scientist Award, Western Regional SNM. Dr. Iagaru published more than 200 papers in peer-reviewed journals, as well as 7 book chapters and 1 book.